This study demonstrates that long-term mineralocorticoid receptor blockade with spironolactone decreased coronary TRPC expression, atherosclerosis, and hypercontractility in the Ossabaw pig model of metabolic syndrome without impacting obesity or glucose tolerance. The gene discussed is NR3C2; the disease is metabolic syndrome.